Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107956 | 0.87 | TK1 (0.34) | TK1ALDH1A1MAPK1 | |
| SCHEMBL3560818 | 0.77 | TK2 (0.38) | TYMPTK1ALDH1A1MAPK1 | |
| SCHEMBL2745270 | 0.75 | MAPT (0.32) | MAPTCYP2C9KMT2ALMNATYMP | |
| SCHEMBL3562767 | 0.75 | LMNA (0.34) | MAPTCYP2C9KMT2ALMNATYMP | |
| SCHEMBL3563252 | 0.74 | ALDH1A1 (0.35) | MAPTCYP2C9KMT2ALMNATYMP | |
| SCHEMBL3560384 | 0.74 | LMNA (0.33) | MAPTCYP2C9KMT2ALMNATYMP | |
| SCHEMBL2745191 | 0.73 | CYP2C9 (0.33) | MAPTCYP2C9KMT2ALMNATYMP | |
| SCHEMBL3560668 | 0.73 | LMNA (0.35) | MAPTCYP2C9KMT2ALMNAALDH1A1 | |
| SCHEMBL3558215 | 0.73 | HPGD (0.33) | MAPTCYP2C9KMT2AALDH1A1HTT | |
| SCHEMBL2745384 | 0.72 | MAPT (0.32) | MAPTCYP2C9KMT2ALMNATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203445-B1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-11-27 | — | — | EP | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| EP-2203445-A1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | Glaxo Group Limited (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009043883-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, DRD5 | MAPT 4521/4885CYP2C9 1455/4885KMT2A 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.